Incidence, characteristics, treatment strategies, and oncologic outcomes of synchronous bilateral upper tract urothelial carcinoma in the Chinese population1These authors contribute equally.

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 2, 2015, Pages 66.e1-66.e11

  Fang, Dong ^a   Xiong, Gengyan ^a   Li, Xuesong ^a   Kang, Yongming ^a,b   Zhang, Lei ^a   Zhao, Guangzhi ^a   Chen, Xiaopeng ^a,c   Yao, Lin ^a   Zhang, Xiaoyu ^a   Yu, Wei ^a   Gong, Kan ^a   Song, Yi ^a   He, Qun ^a   He, Zhisong ^a   Zhou, Liqun ^a   Guo, Yinglu ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b SUINING CENTRAL HOSPITAL   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bilateral; Chronic kidney disease (CKD); Nephron sparing surgery (NSS); Radical nephroureterectomy (RNU); Sex; Upper tract urothelial carcinoma (UTUC)

Indexed keywords

ARISTOLOCHIC ACID;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BILATERAL CANCER; BLADDER TUMOR; CANCER GRADING; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CHINESE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTECTOMY; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHRON SPARING SURGERY; NEPHROURETERECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PELVIS SURGERY; PREOPERATIVE EVALUATION; PREVALENCE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; SEX DIFFERENCE; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; URINE CYTOLOGY;

EID: 84923343335     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.07.001     Document Type: Article

References (30)

1. Munoz J.J., Ellison L.M. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol 2000, 164:1523-1525.
2. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1998. CA Cancer J Clin 1998, 48:6-29.
3. Holmang S., Johansson S.L. Synchronous bilateral ureteral and renal pelvic carcinomas: incidence, etiology, treatment and outcome. Cancer 2004, 101:741-747.
4. Kang C.H., Yu T.J., Hsieh H.H., Yang J.W., Shu K., Shiue Y.L. Synchronous bilateral primary transitional cell carcinoma of the upper urinary tracts: ten patients with more than five years of follow-up. Urology 2004, 63:380-382.
5. Tai H.C., Lai M.K., Chung S.D., Huang K.H., Chueh S.C., Yu H.J. Intermediate-term oncological outcomes of hand-assisted laparoscopic versus open bilateral nephroureterectomy for dialysis and kidney transplant patients with upper urinary tract urothelial carcinoma. J Endourol 2009, 23:1139-1144.
6. Cummings K.B. Nephroureterectomy: rationale in the management of transitional cell carcinoma of the upper urinary tract. Urol Clin North Am 1980, 7:569-578.
7. Colin P., Ouzzane A., Pignot G., et al. Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. BJU Int 2012, 110:1134-1141.
8. Gadzinski A.J., Roberts W.W., Faerber G.J., Wolf J.S. Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol 2010, 183:2148-2153.
9. Lughezzani G., Jeldres C., Isbarn H., et al. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur J Cancer 2009, 45:3291-3297.
10. Fajkovic H., Klatte T., Nagele U., et al. Results and outcomes after endoscopic treatment of upper urinary tract carcinoma: the Austrian experience. World J Urol 2013, 31:37-44.
11. Ma Y.C., Zuo L., Chen J.H., et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006, 17:2937-2944.
12. Nortier J.L., Martinez M.C., Schmeiser H.H., et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000, 342:1686-1692.
13. Chen C.H., Dickman K.G., Huang C.Y., et al. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes. Int J Cancer 2013, 133:14-20.
14. Li X.B., Xing N.Z., Wang Y., Hu X.P., Yin H., Zhang X.D. Transitional cell carcinoma in renal transplant recipients: a single center experience. Int J Urol 2008, 15:53-57.
15. Milojevic B., Djokic M., Sipetic-Grujicic S., et al. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma. Urol Oncol 2013, 31:1615-1620.
16. Li C.C., Chang T.H., Wu W.J., et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol 2008, 54:1127-1134.
17. Lughezzani G., Sun M., Perrotte P., et al. Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the Surveillance, Epidemiology, and End Results database. Urology 2010, 75:321-327.
18. Yu W., Zhao Y.Y., Shen Q., et al. Gender-related differences in pathological characteristics of upper urinary tract urothelial carcinoma: analysis of 597 cases. Beijing Da Xue Xue Bao 2011, 43:522-524.
19. Chen X.P., Xiong G.Y., Li X.S., et al. Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: experience from a nationwide high-volume centre in China. BJU Int 2013, 112:917-924.
20. Miyake H., Hara I., Kamidono S., Eto H. Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns. J Urol 2004, 172:1127-1129.
21. Millan-Rodriguez F., Chechile-Toniolo G., Salvador-Bayarri J., Huguet-Perez J., Vicente-Rodriguez J. Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. J Urol 2000, 164:1183-1187.
22. Cosyns J.P., Jadoul M., Squifflet J.P., Wese F.X., van Ypersele de Strihou C. Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis 1999, 33:1011-1017.
23. Wang S.M., Lai M.N., Chen P.C., Wang J.D. Increased risk of urothelial cancer in young and middle aged patients with end-stage renal disease. J Formos Med Assoc 2013.
24. Chung S.D., Huang K.H., Lai M.K., et al. CKD as a risk factor for bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. Am J Kidney Dis 2007, 50:743-753.
25. Fang D., Zhang L., Li X., et al. Risk factors and treatment outcomes of new contralateral upper urinary urothelial carcinoma after nephroureterectomy: the experiences of a large Chinese center. J Cancer Res Clin Oncol 2014, 140:477-485.
26. Milenkovic-Petronic D., Milojevic B., Djokic M., et al. The impact of tumor size on outcomes in patients with upper urinary tract urothelial carcinoma. Int Urol Nephrol 2014, 46:563-569.
27. Espiritu P.N., Sverrisson E.F., Sexton W.J., et al. Effect of tumor size on recurrence-free survival of upper tract urothelial carcinoma following surgical resection. Urol Oncol 2014, 32:619-624.
28. Pieras E., Frontera G., Ruiz X., Vicens A., Ozonas M., Piza P. Concomitant carcinoma in situ and tumour size are prognostic factors for bladder recurrence after nephroureterectomy for upper tract transitional cell carcinoma. BJU Int 2010, 106:1319-1323.
29. Silberstein J.L., Power N.E., Savage C., et al. Renal function and oncologic outcomes of parenchymal sparing ureteral resection versus radical nephroureterectomy for upper tract urothelial carcinoma. J Urol 2012, 187:429-434.
30. Azemar M.D., Comperat E., Richard F., Cussenot O., Roupret M. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. Urol Oncol 2009, 29:130-136.